«

»

Dec 26

Thoughts Regarding LDL-P, ApoB, and Remnants

This week, Peter Attia released Measuring cardiovascular disease risk and the importance of apoB on his blog. I think it’s well worth the read and highly encourage you to finish it first before reading the rest of this article.

One quote in particular sums the article up well:

While I have historically used LDL-P and apoB metrics somewhat interchangeably, one advantage of measuring apoB over LDL-P is that apoB encompasses all of the potentially atherogenic particles: not just LDLs, but VLDLs, Lp(a), IDLs, and potentially chylomicrons. And this point has me relying more and more heavily on apoB today than on LDL-P in my patients and myself.

Understanding Remnants

Generally speaking, particles that are neither LDL nor HDL are considered “remnants” in the literature. (There’s some further distinction regarding Lp(a) and fully lipidated Chylomicrons in rare circumstance regarding this topic, but we’ll cover that in future article).

In other words, we have three categories of lipoproteins as labeled:

  • HDL particles (HDL-P)
  • LDL particles (LDL-P)
  • Remnants (all non-LDL-P, non-HDL-P particles)

Here’s a good summation from Wikipedia regarding Remnant cholesterol:

Remnant cholesterol, also known as remnant lipoprotein, is a very atherogenic lipoprotein composed primarily of very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL). Stated another way, remnant cholesterol is all plasma cholesterol that is not LDL cholesterol or HDL cholesterol, which are triglyceride-rich lipoproteins. Nonetheless, remnant cholesterol is primarily chylomicron and VLDL from which most triglyceride has been removed, such that each remnant particle contains about 40 times more cholesterol than LDL.

(Emphasis mine)

Which Lipoproteins have ApoB?

So which lipoproteins have this ApoB we’re talking about? That’s easy – basically every lipoprotein that isn’t an HDL*.

  • HDL particles (has no ApoB)
  • LDL particles (has ApoB)
  • Remnants (has ApoB)

* [If you want get technical, there’s some differences in opinion in the inclusion/exclusion of lipid-rich chylomicrons and Lp(a), with most leaning toward exclusion.]

I actually wrote an article on remnants two years ago and included it in my presentation at Low Carb Breckenridge a few months later.

Many people (myself included, originally) used LDL-P and ApoB interchangeably given the vast majority of “ApoB-containing Lipoproteins” in our bloodstream at any given time was likely to be LDL particles (LDL-P). My opinion on this definitely changed the more the Lipid Energy Model developed, because I could see how remnants uniquely told a story of the problem that LDL particles could not.

A Simple Boat Analogy

Imagine a fleet of cargo ships that are constantly being deployed and have two jobs:

  1. Deliver goods, which takes 1 hour
  2. Patrol and help out, which they do for 72 hours

You wouldn’t be surprised to see about 1 in 73 of these cargo ships having cargo and the rest being generally empty at any given time. Maybe some timing on launch or deliveries offsets this slightly so it’s more like 1 in 50 at times, or 1 in 100 other times.

Now let’s change it. What if you’re not seeing just one cargo ship full of cargo, you see 5. What does that mean?

You investigate further and find that there’s a reduced ability of these ships to deliver their cargo. They’re having a hard time completing their first job — the same job that should’ve been easy and take much less time on turnaround.

Maybe there’s a problem with the docks or rockier waters or the boats themselves. Regardless, you see more boats with cargo undelivered seems to associate with bad outcomes so you start to take notice.

Yet conversely, you notice that no matter how many more total boats you have, there seems to be very few bad outcomes when at any given time there are very few that have cargo — suggesting they are making their deliveries properly.

ApoB “Boats” Failing to Deliver

Most ApoB-containing Lipoproteins like chylomicrons and VLDL have a first job: to deliver their fat-based energy (triglycerides) to cells, and in normal circumstances it should happen very quickly (typically less than an hour). Then a large portion of VLDL will ultimately remodel to LDL particles and remain in the bloodstream for 2-4 days.

So let’s recreate our boat job list from above:

  1. Deliver triglycerides, which typically takes less than an hour
  2. Remain in the bloodstream (potentially immune/repair) for 2-4 days

But what do we commonly see in those who are obese, Type 2 Diabetic, or suffering other metabolic derangements?

  • High fasting VLDL
  • High fasting Triglycerides
  • And thus, high overall remnants

I posit the simple explanation in most of these cases is that there is a clearly reduced capability on the part of the existing VLDLs to make their deliveries (job #1), which matches up well with one being past the “personal fat threshold“. There’s little parking left for the triglycerides, so we see an accumulation of fat in tissues that aren’t designed to store it, such as ectopic fat.

This from a great paper that illustrates this dynamic well:

Visceral fat is considered by many to behave as an ectopic fat depot, accumulating triglycerides (TG’s) when body fat storage needs exceed the capacity of subcutaneous fat depots to function normally 

Talking LDL-P and ApoB with Attia

For those who managed to make it through the 3.5 hour podcast Peter and I had, you’ll note I kept bringing up this context often when I was outlining my dream request list on data. Peter was seeking to be helpful in talking about what datsets might have what I was looking for.

Here’s Peter:

The Quebec Heart Study, here I printed it up here. I mean, basically it’s showing it has nothing to do with the LDLC once you know the ApoB. Look at the risk.

After some further back-and-forth I managed to clarify better:

Triglycerides, HDL, and preferably LDLP. Now, there is an important distinction we’ve gotta make with ApoB, because ApoB can, in theory, also include remnant lipoproteins.

Peter agreeing on that note for what I’m looking for:

Yeah, LDL-P is more accurate than ApoB.

[Full transcript of this portion of the podcast can be found here]

Thus far, I haven’t gotten ahold of dataset where I can do that stratification, but I certainly appreciate Peter’s interest in talking about it and his consideration in helping out. (An additional aside to Peter’s credit, he further offered to cover a visit to a National Lipid Association conference where I could’ve met with lipidologists on this very topic).

Are LDLs Getting the Blame for Remnants When Viewing only ApoB?

If one has high triglycerides, one almost certainly has high remnants, given they are triglyceride rich — much more so than LDL particles.

And given high triglycerides typically result in lower HDL (that’s a mechanistic discussion for another day), it’s understandable why this dysregulation would further associate with ectopic fat and yes, cardiovascular disease. (This profile is already recognized in the literature as Atherogenic Dyslipidemia)

Which brings us right back to the “Low Carb Cholesterol Challenge“. I believe the reason we’re having trouble finding studies where high LDL is shown to be atherogenic where HDL is high and TG low is that we are seeing low overall remnants, suggesting a more optimal lipid metabolism. One that is likely functioning well by comparison to one with low HDL and high triglycerides. (To date, we still haven’t had the challenge met.)

Moreover, it makes a lot of sense why one could have higher LDL due to longer residence time of remnants — thus having a higher marginal LDL for a negative reason. The tip off for whether this is the case being high VLDL and triglycerides. But this too is a hypothesis that I’m actively testing.

Final Thought

My larger point is that it is certainly my expectation that looking at ApoB by itself would likely show a greater association with cardiovascular disease given it lumps LDL-P with remnants. But I likewise expect we’d see a much stronger association with cardiovascular disease when looking at remnants without LDL-P.

…Addendum

I realized after posting this that I oddly forgot to mention the LMHR Measurement Project and how our current efforts will actually test the very hypothesis I mention above. Shame on me!

Yes, if you — like me — would want to see if those with very high LDL-P and ApoB would see greater cardiovascular risk at a population level in spite of having low remnants and triglycerides, considering contributing to the project as we’re getting closer to reaching our funding goal. Thanks!

14
Leave a Reply

avatar
 
Photo and Image Files
 
 
 
Audio and Video Files
 
 
 
Other File Types
 
 
 
6 Comment threads
8 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
9 Comment authors
Brian Edwards MDSiobhan HugginsJosh CosfordJanet DunawayColleen Recent comment authors

  Subscribe  
newest oldest most voted
Notify of
David Rice
Guest
David Rice

Thanks, Dave. This makes so much sense from a ‘system’ standpoint. It seems like it takes an engineer (over a scientist or doctor) to figure that out. I am an engineer also and I just get frustrated with the lack of a holistic view of the way the body operates among the scientific community.

Paul Melzer
Member
Paul Melzer

Thanks again for your great work, Dave. Glad to be a supporter (albeit a modest one)!

Siobhan Huggins
Admin

And thanks for your support! 🙂

Janet Dunaway
Guest
Janet Dunaway

Thank you, Dave for all your hard work! I recently had labs and a CAC done and would like some opinions on my results. My doctor wants to put me on a statin and I do not want to go on one. . I’m really not sure how to interpret these numbers.If anyone can shed some light on my results, I would be very grateful.
Apo B 166 mg/dl
Chol/HDL ratio 4.6 calc
TC 375 mg/dl
HDL 81 mg/dl
HDL large 5070 mmol/L
HS CRP 5.1 ( I have Rheumatoid Arthritis–in remission)
LDL Medium 312 nmol/L
LDL Particle Number 2084 nmol/L
LDL pattern A
LDL peak size 229.9 Angstrom
LDL small 186 nmol/L
LDL Cholesterol 276 mg/dl
Lipoprotein (a) <10 nmol/L
LP PLA2 Activity 178 nmol/min/mLH
Non HDL Cholesterol 294 mg/dl (calc)
TG 77 mg/dl
CAC score: 60.4
Left main Artery 0
Left Anterior Descending Artery 60.4
Left circumflex artery 0
Right coronary artery 0
I am 53 years old, extremely active, and zero carb.
Thanks in advance for any insight!
Janet

Colleen
Guest
Colleen

20 years on a statin can yield bad results (as I’ve seen in my mother). How long zero carb? Any prior CAC? How about maintaining for 6 mos or 1 year and redoing the CAC. If no progression, then why take a statin? Also could do carotid measurements and follow that. Dave’s receded on low carb. See his post on that.

Janet Dunaway
Guest
Janet Dunaway

Hi Colleen,
Thank you for your response. I was Keto for one year and have been zero carb since August 2019. Never had a prior CAC. My doctor freaked out at my results, but I told him about Dave’s research and that I feel better than I have ever felt in my life. I’m off all RA meds since going zero carb, almost off antidepressants and anti-anxiety meds. I told him I would not take a statin. I started taking Vitamin K2 MK7 (I think that’s what it’s called) to help reduce the CAC score (heard about that from Ivor Cummins).
I’ll take a look at Dave’s post.
Thanks again!
Janet

Brian Edwards MD
Guest

Did your Doc offer Zetia and Enduracin? Not statins.

Steps:
1-Endur-acin (over the counter niacin) is a proprietary wax matrix that does not cause flushing. Take only 1,000 mg a day.
2-After a month if not at non-HDLc goal, add one half tab Zetia (now generic Ezetimibe 10 mg)
3-After another month if non-HDLc not at goal, take full pill of Zetia.
4- After another month if non-HDLc not at goal get Lipitor 10 mg (now generic atorvastatin) take one half tab a day.
5- Now on triple low dose medications, if non-HDLc not at goal increase to full tablet of Lipitor 10 mg.

Annlee
Guest
Annlee

You quoted Wikipedia:
Remnant cholesterol, also known as remnant lipoprotein, is a very atherogenic lipoprotein composed primarily of very low-density lipoprotein (VLDL) and intermediate-density lipoprotein (IDL).
“… very atherogenic lipoprotein” bothers me, as it implies a causal relationship (athero + genesis). Is there, to your knowledge, any evidence/plausible mechanism for a causal relationship, or are they merely (again!!) misstating a correlation? I note that the remnants definition does not seem to include oxLDL (if I understand correctly), which may be implicated in the causal chain of atherosclerosis, though not necessarily as the initiator of that chain.

Many thanks for all you and your cohorts are doing in this.

Siobhan Huggins
Admin

I believe it’s merely a correlation, restated it would likely say “high levels of remnant lipoproteins are highly associated with atherogenesis”. Which would make sense as the situations where you’d have chronically high remnant lipoproteins going around all the time would be the same that you’d expect to see in someone who was sick and more likely to develop heart disease (diabetes, metabolic syndrome, etc). But, no, I don’t think I’ve ever seen strong causal evidence for remnants *causing* heart disease. This type of language, I’ve noticed, isn’t necessarily uncommon in the research – but that’s a larger discussion in itself.

John Wohlwend
Member
John Wohlwend

Hi Dave

I can’t seem to find anywhere a desired level of remnant cholesterol. What do we want it to be?

Annlee
Guest
Annlee

https://cholesterolcode.com/low-carb-breck-18-and-an-update-on-remnant-cholesterol/ Has some indicated cut points – there may be something more recent, but I haven’t seen it.

Siobhan Huggins
Admin

Hi, unfortunately the studies we’ve found so far haven’t included *fasting* remnant cholesterol, which I would personally find quite important – the studies we’ve seen thus far when looking at All-Cause Mortality tend to use non-fasting measures. Although we’re not doctors, it’s probably safe to say, that if triglycerides are low remnants will also be low just as a rule of thumb.

Josh Cosford
Guest
Josh Cosford

I just got my lip panel back, and I have confusing Apolipoprotein B and remnant cholesterol results.
TG = 0.62 mmol/L
Total C = 7.64 mmol/L
HDL-C = 1.61 mmol/L
LDL-C = 5.75 mmol/L
Apo B = 1.70 g/L (normal is supposed to be 0.8 associeated with CD)

If you run the calculations, my other markers are good:
Remnant-C = 0.28 mmol/L
TG:HDL Ratio = 0.39

Should I be worried about my 1.70 g/L Apo B when my remnant cholesterol is so low? My test was after 18 hours fasted, and a few weeks of carnivore prior (was keto anyway before carnivore). My initial feeling is that my Apo B is just high because my LDL-C is so high from 18
hours fasted. Thanks!

Josh

Siobhan Huggins
Admin

Hi – we can’t really say whether you should be worried or not, as we’re not doctors. As is true for LDL and risk, everyone has to read the research and come to their own conclusions on what they feel comfortable with. As discussed in the post, it’s likely that high apoB in general is reflecting high *remnants* (paired with high triglycerides) and this might be why it’s more predictive than LDL-C alone. But plenty of lipidologists argue that all apoB containing lipoproteins are “atherogenic”. Likely, what I’d do in your situation is read the case made by several perspectives and decide for yourself, since the context of high apoB without metabolic syndrome is – I think – not entirely clear.

Some perspectives from people on the more cautiously pessimistic side would be people like Thomas Dayspring, Peter Attia, and Spencer Nadolsky – all are great resources. 🙂
You may also want to check out the Cholesterol Code facebook group as there is plenty of research papers and discussion there on this very topic!